{"name":"G1 Therapeutics","slug":"g1-therapeutics","ticker":"GTHX","exchange":"NASDAQ","domain":"g1therapeutics.com","description":"G1 Therapeutics, Inc. is an American biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company specializes in developing and commercializing small molecule therapeutics for the treatment of patients with cancer.","hq":"Durham, NC","founded":0,"employees":"","ceo":"Jack Bailey","sector":"Oncology / Supportive Care","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$450M","metrics":{"revenue":82511000,"revenueGrowth":60.8,"grossMargin":0,"rdSpend":43711000,"netIncome":-47967000,"cash":121540000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Trilaciclib patent cliff ($0.0B at risk)","drug":"Trilaciclib","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cylophosphamide","genericName":"Cylophosphamide","slug":"cylophosphamide","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Cylophosphamide","genericName":"Cylophosphamide","slug":"cylophosphamide","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"G1 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"G1 Therapeutics reported its fourth quarter and full year 2023 financial results, which included revenue of $13.4 million and a net loss of $24.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"G1 Therapeutics Announces Exclusive Distribution Agreement with Sandoz for Trilaciclib in the US","summary":"G1 Therapeutics announced an exclusive distribution agreement with Sandoz for trilaciclib in the US, which will enable Sandoz to commercialize trilaciclib in the US market.","drugName":"","sentiment":"positive"},{"date":"2023-09-18","type":"regulatory","headline":"FDA Approves Trilaciclib for Use in Combination with Chemotherapy for the Treatment of Small Cell Lung Cancer","summary":"The FDA approved trilaciclib for use in combination with chemotherapy for the treatment of small cell lung cancer, marking the first approval of a CDK4/6 inhibitor in the US.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxObXk3YndPVl9GLVNfd3N4OFFTOFk2M3g4MG1wTlFIY0NIOGRhdUh5aEl6RkZrZkFoQTVHOW9tMm5ETDMxNUpTdVZxU1pJTWVXZU1SQk13TTFhVGFZcVdSRlJLMGZKajdOM2IyQmRWNGNaWV9HVFQzNWRjTXZ5bFZMejFabnE5d2RrQkJtV3R4OXV3ME50Wmd1MGlCVlVBeW5JcGhKWHQxNjRDWDcxME9LcnRHdWg3RXFmSmxBcHZB?oc=5","date":"2024-09-18","type":"pipeline","source":"Stock Titan","summary":"Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer - Stock Titan","headline":"Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQTjdqZXlBa2pRUjlGbUpFVS1feHhkWVJsT0hLVnFTMkhxRDdaZF9NNl9yRVFqXzRRNDJKZ0h1dkpGUzE3dkswbHlnRDZBa2F4R0M0TWdOQWFWdFczTDV2TGFkUGc0LVJXbjhZTjJJeF9PLXZRdFFmNjRjYXhraVBxSHVwTlpVWm9aNmNKdldqbzZMVGc?oc=5","date":"2024-09-18","type":"pipeline","source":"Yahoo Finance","summary":"Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer - Yahoo Finance","headline":"Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPYkJNSGRPa2xwSFkyLTYycWxlTm9ScmNFUUpKS3hrRXZBMDZYMXh1WXlEdG9GS3ZWLVM5MDR3Q2pvcWdBaDlTUW5lcTRGMWlIMi05SU1xbkdDVXJoMHpxeWV0MmxNN1pwV3IwcW50OGFWZk1qVDJpY1h5LS1ISmtWVWRyMDBjdkVqNXZSOUpJZ2t6aW4tdi1LTmZWRm1ENzExY1NSMHoyaWM5LWc?oc=5","date":"2024-08-08","type":"deal","source":"The Business Journals","summary":"In $400M deal for Triangle firm, familiar name is largest shareholder - The Business Journals","headline":"In $400M deal for Triangle firm, familiar name is largest shareholder","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPNktSSUJ0d1RYTUVjbS1NUFRQd0FSMFVBR0d0aEZJYlhFQ2NHTUlnM2NRYktWOF9Ca2dhS2FDS0NVZGlUeW4yRXExRDRqb0xNaGZiR3o2SDhNbXlJcTE5SmpNSWV5RTd3NF9tb3hyUkJDbmx6UTE4LTFtX1lUdTVNYS1XNEpaTXc?oc=5","date":"2024-08-07","type":"pipeline","source":"InvestorPlace","summary":"Why Is G1 Therapeutics (GTHX) Stock Up 66% Today? - InvestorPlace","headline":"Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOSGhfdWF6NHJtaXlHeG5uTm9JYmRBd05yYnhlbUl1NDhMUlNzSHc4VnM0RVRGUk55ZzRmbEExMThSWU12TEN1R0tDdTF2bHFYbjZRbmRqa0pfd2c1VkM3dG1weE1JRVVCeXFCX0c4ZkhvaXg3VFpnc3VWWWhoMGo5Z2I1a3dJY2swdk1JNVFRcWdnNU1GM3BXcTduYUJrZ1FMZGtOQVhqVWgyY3RXeHI0dS1WMm9zbm1X?oc=5","date":"2024-08-07","type":"deal","source":"globenewswire.com","summary":"Pharmacosmos Group to Acquire G1 Therapeutics - globenewswire.com","headline":"Pharmacosmos Group to Acquire G1 Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNZ3ZFVjNpMmJrM2tLWXpoWFQ3RGpGTUMwTzF5WG1IUFJNTE9xNF9ubWR4N0xycHdWUTgwQTdHUmlHbDdtRVVDTDRzRVhFaGxkU1ZERmM2dmRtbjh6YzNvM0lpTXQ1V0hZam5iejAyZWt4ZmMwUHpGN0htSUZ5bFUzNmtWM1VGQVlvcW50a2dGeW9uVk1CRTROd0JEemNQdw?oc=5","date":"2024-08-07","type":"pipeline","source":"MedCity News","summary":"Path Forward for Cancer Biotech G1 Therapeutics Is $405M Acquisition by Pharmacosmos - MedCity News","headline":"Path Forward for Cancer Biotech G1 Therapeutics Is $405M Acquisition by Pharmacosmos","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQU2czQW5PYml1b1lpcEQ2cnJ6LThNQ2I5ZUpVYUtoTEViMnZtTlF6NnFBbHYxcmhfZFM5QWdWQnUzTUxkX1VCTm5NaW1xVllMWUtKb0l1djdtZkZPRUFQVFVfZzVpRTZZYnRtZGhQeUVIVzlIbXNKbnNnbzVpMnpzVDNvR3VNdGpVcG1JWE01Rk5pRm52Z0dnTXZIWWs3N0pFZFVZNlFBR2RtTmFCQkx3TQ?oc=5","date":"2024-08-07","type":"deal","source":"Investing.com UK","summary":"Pharmacosmos to acquire G1 Therapeutics for $405 million By Investing.com - Investing.com UK","headline":"Pharmacosmos to acquire G1 Therapeutics for $405 million By Investing.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQcFJqSXBaS0xQUzRCcFpJRzc4UjRfU3dVeVJ3bEZhUXM0aU1SUXgxaUJnMUZieE5IUl9UOXNiNWlJOGFDMlJGYVFRMGlZVHBJOFpQYVFxODVjQTk2dlpXVUZxLWhsTUpoTndoeTN2aUliZW16SW9QVklnTUxQRmRielJmaUxZTDZTbFpCU3d0cThDUQ?oc=5","date":"2023-02-13","type":"pipeline","source":"InvestorPlace","summary":"Why Is Sorrento Therapeutics (SRNE) Stock Down 40% Today? - InvestorPlace","headline":"Why Is Sorrento Therapeutics (SRNE) Stock Down 40% Today?","sentiment":"neutral"}],"patents":[{"drugName":"Trilaciclib","drugSlug":"trilaciclib","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Clovis Oncology","AstraZeneca","Pfizer"],"therapeuticFocus":["Oncology","Supportive Care"],"financials":{"source":"sec_edgar+yahoo","revenue":82511000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":82511000,"period":"2023-12-31"},{"value":51301000,"period":"2022-12-31"},{"value":51301000,"period":"2022-12-31"},{"value":10250000,"period":"2022-12-31"},{"value":23576000,"period":"2022-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":43711000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-47967000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":121540000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}